244 related articles for article (PubMed ID: 28257394)
1. Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma.
Blasig H; Bender C; Hassel JC; Eigentler TK; Sachse MM; Hiernickel J; Koop A; Satzger I; Gutzmer R
Melanoma Res; 2017 Aug; 27(4):321-325. PubMed ID: 28257394
[TBL] [Abstract][Full Text] [Related]
2. Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis.
Quiroga D; Liebner DA; Philippon JS; Hoffman S; Tan Y; Chen JL; Lenobel S; Wakely PE; Pollock R; Tinoco G
BMC Cancer; 2020 Jun; 20(1):527. PubMed ID: 32503455
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases.
Jacobsoone-Ulrich A; Jamme P; Alkeraye S; Dzwiniel V; Faure E; Templier C; Mortier L
Melanoma Res; 2016 Apr; 26(2):153-6. PubMed ID: 26636908
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab.
Nomura M; Otsuka A; Kondo T; Nagai H; Nonomura Y; Kaku Y; Matsumoto S; Muto M
Cancer Chemother Pharmacol; 2017 Nov; 80(5):999-1004. PubMed ID: 28983657
[TBL] [Abstract][Full Text] [Related]
5. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
[TBL] [Abstract][Full Text] [Related]
6. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
7. Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission.
Sadrolashrafi K; Samlowski W
Oncologist; 2023 May; 28(5):e270-e275. PubMed ID: 36852837
[TBL] [Abstract][Full Text] [Related]
8. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
9. Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients.
DeTemple VK; Hassel JC; Sachse MM; Grimmelmann I; Leiter U; Gebhardt C; Eckardt J; Pföhler C; Angela Y; Hübbe H; Gutzmer R
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358887
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD1-induced collagenous colitis in a melanoma patient.
Baroudjian B; Lourenco N; Pagès C; Chami I; Maillet M; Bertheau P; Bagot M; Gornet JM; Lebbé C; Allez M
Melanoma Res; 2016 Jun; 26(3):308-11. PubMed ID: 26990271
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.
Betof Warner A; Palmer JS; Shoushtari AN; Goldman DA; Panageas KS; Hayes SA; Bajwa R; Momtaz P; Callahan MK; Wolchok JD; Postow MA; Chapman PB
J Clin Oncol; 2020 May; 38(15):1655-1663. PubMed ID: 32053428
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.
Ribeiro Gomes J; Schmerling RA; Haddad CK; Racy DJ; Ferrigno R; Gil E; Zanuncio P; Buzaid AC
J Immunother; 2016; 39(9):367-372. PubMed ID: 27741091
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of immunotherapy for metastatic mucosal melanoma.
Shreders A; Joseph RW
Immunotherapy; 2016 Jul; 8(8):843-5. PubMed ID: 27381682
[No Abstract] [Full Text] [Related]
18. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in melanoma: Recent advances and future directions.
Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report.
Kwatra V; Karanth NV; Priyadarshana K; Charakidis M
J Med Case Rep; 2017 Mar; 11(1):73. PubMed ID: 28315636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
